Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Obinna Uzodinma

Anesthesiology Dallas, TX Medical Doctor

NPI 1841521812 CMS profile 219432

12222 Merit Dr Ste 600, Dallas, TX 75251

Open in the dashboard

General payments

$17,274

390 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Obinna Uzodinma of Dallas, TX is reported in the CMS Open Payments database as having received $17,274 across 390 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,014 6
2022 General $396 20
2021 General $3,380 113
2020 General $2,411 111
2019 General $3,072 140

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Obinna Uzodinma
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to Obinna Uzodinma were reported at $8,014. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year Obinna Uzodinma Anesthesiology median Middle half National median
2019 $3,072 $72 $23–$151 $163
2020 $2,411 $36 $17–$120 $114
2021 $3,380 $49 $21–$135 $132
2022 $396 $52 $22–$144 $149
2023 $0 $53 $23–$143 $160
2024 $0 $55 $25–$150 $164
2025 $8,014 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. B. Braun Medical Inc. $8,014 6 payments
  2. RedHill Biopharma Inc. $984 9 payments
  3. Nevro Corp. $894 16 payments
  4. Abbott Laboratories $828 23 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $711 41 payments
  6. Medtronic USA, Inc. $642 19 payments
  7. Supernus Pharmaceuticals, Inc. $610 35 payments
  8. Collegium Pharmaceutical, Inc. $585 43 payments
  9. Medtronic, Inc. $505 11 payments
  10. Boston Scientific Corporation $451 26 payments
  11. Other $3,050 161 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,430 383 payments
  2. Consulting Fee $7,790 3 payments
  3. Travel and Lodging $1,054 4 payments
Products named General payments · program years 2019–2025
  1. INTROCAN SAFETY $8,014 6 payments
  2. Movantik $964 8 payments
  3. RELISTOR $711 41 payments
  4. XTAMPZA $585 43 payments
  5. Proclaim Family of SCS IPGs $502 16 payments
  6. RESTORE $490 12 payments
  7. Senza Spinal Cord Stimulation System $462 8 payments
  8. TROKENDI XR $457 27 payments
  9. Omnia $432 8 payments
  10. INTELLIS $399 9 payments
  11. Other $4,696 232 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

390 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anesthesiology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record